WallStreetZen

NASDAQ: NVAX
Novavax Inc Stock

$172.52+0.78 (0.45%)
Updated May 6, 2021
NVAX Price
$172.52
Fair Value Price
N/A
Market Cap
$10.98B
52 Week Low
$19.62
52 Week High
$331.68
P/E
-23.73x
P/B
17.51x
P/S
13.49x
PEG
N/A
Dividend Yield
0%
Revenue
$475.60M
Earnings
-$418.26M
Gross Margin
100%
Operating Margin
-84.76%
Profit Margin
-87.9%
Debt to Equity
1.52
Operating Cash Flow
-$43M
Beta
0.94
Next Earnings
May 10, 2021
Ex-Dividend
N/A
Next Dividend
N/A

NVAX Overview

Zen Score

High
Medium
Low
29
Industry average

Reasons for this score

NVAX is poor value based on its book value relative to its share price (17.51x), compared to the US market average (0.6x)
Valuation
NVAX is poor value based on its book value relative to its share price (17.51x), compared to the US Biotechnology industry average (6.01x)
Valuation
NVAX's cash and short-term investments ($806.39M) can cover NVAX's cash burn for the next year ($97.16M), even accounting for increasing cash burn (70.23%)
Financials

1 of 7

NVAX News

Valuation

NVAX fair value

Fair Value of NVAX stock based on Discounted Cash Flow (DCF)
Price
$172.52
Fair Value
$180.16
Undervalued by
4.24%

NVAX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-23.73x
Industry
66.59x
Market
27.98x

NVAX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
17.51x
Industry
6.01x
Market
0.6x
NVAX is poor value based on its book value relative to its share price (17.51x), compared to the US market average (0.6x)
Valuation
NVAX is poor value based on its book value relative to its share price (17.51x), compared to the US Biotechnology industry average (6.01x)
Valuation

NVAX's financial health

Profit margin

Revenue
$279.7M
Net Income
-$177.6M
Profit Margin
-63.5%
NVAX's cash and short-term investments ($806.39M) can cover NVAX's cash burn for the next year ($97.16M), even accounting for increasing cash burn (70.23%)
Financials
NVAX's profit margin has increased (+623.1%) in the last year from (-711%) to (-87.9%), but it is still unprofitable
Financials

Assets to liabilities

Assets
$1.6B
Liabilities
$955.3M
Debt to equity
0.75
NVAX's short-term assets ($1.25B) exceed its short-term liabilities ($579.67M)
Financials
NVAX's short-term assets ($1.25B) exceed its long-term liabilities ($375.60M)
Financials
NVAX's debt has increased relative to shareholder equity (1.52), over the past 5 years ago (0.32)
Financials
NVAX's debt to equity ratio (1.52) is considered high
Financials

Cash flow

Operating
-$128.6M
Investing
-$31.1M
Financing
$404.6M
NVAX's cash and short-term investments ($806.39M) can cover NVAX's cash burn ($97.16M) for at least 1 year
Financials

Novavax Stock FAQ

What is Novavax's quote symbol?

(NASDAQ: NVAX) Novavax trades on the NASDAQ under the ticker symbol NVAX. Novavax stock quotes can also be displayed as NASDAQ: NVAX.

What is the 52 week high and low for Novavax (NASDAQ: NVAX)?

(NASDAQ: NVAX) Novavax's 52-week high was $331.68, and its 52-week low was $19.62. It is currently -47.99% from its 52-week high and 779.31% from its 52-week low.

How much is Novavax stock worth today?

(NASDAQ: NVAX) Novavax currently has 63,659,952 outstanding shares. With Novavax stock trading at $172.52 per share, the total value of Novavax stock (market capitalization) is $10.98B.

Novavax stock was originally listed at a price of $100.00 in Dec 31, 1997. If you had invested in Novavax stock at $100.00, your return over the last 23 years would have been 72.52%, for an annualized return of 2.4%.

How much is Novavax's stock price per share?

(NASDAQ: NVAX) Novavax stock price per share is $172.52 today (as of May 6, 2021).

What is Novavax's Market Cap?

(NASDAQ: NVAX) Novavax's market cap is $10.98B, as of May 9, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Novavax's market cap is calculated by multiplying NVAX's current stock price of $172.52 by NVAX's total outstanding shares of 63,659,952.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.